 Andrew Wolf
Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 3 | 2024 | 380 | 1.280 |
Why?
| | Students, Nursing | 2 | 2018 | 58 | 1.170 |
Why?
| | Education, Nursing | 2 | 2018 | 80 | 1.160 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.890 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2024 | 69 | 0.860 |
Why?
| | Alzheimer Disease | 5 | 2016 | 438 | 0.830 |
Why?
| | Meningitis | 1 | 2023 | 74 | 0.820 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 98 | 0.790 |
Why?
| | Writing | 1 | 2022 | 85 | 0.750 |
Why?
| | Serum Sickness | 1 | 2019 | 7 | 0.690 |
Why?
| | Rituximab | 1 | 2019 | 149 | 0.640 |
Why?
| | Videotape Recording | 1 | 2018 | 30 | 0.630 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 337 | 0.630 |
Why?
| | Immunologic Factors | 1 | 2019 | 219 | 0.590 |
Why?
| | Superior Colliculi | 1 | 2015 | 33 | 0.500 |
Why?
| | Internet | 1 | 2018 | 601 | 0.470 |
Why?
| | Apolipoproteins E | 1 | 2012 | 81 | 0.420 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2012 | 48 | 0.400 |
Why?
| | Energy Metabolism | 2 | 2016 | 713 | 0.390 |
Why?
| | Mitochondrial Diseases | 1 | 2012 | 77 | 0.380 |
Why?
| | Models, Neurological | 1 | 2012 | 213 | 0.370 |
Why?
| | Motor Activity | 1 | 2015 | 635 | 0.360 |
Why?
| | Strabismus | 2 | 2007 | 26 | 0.350 |
Why?
| | Decision Making | 1 | 2015 | 791 | 0.320 |
Why?
| | Dietary Supplements | 1 | 2012 | 460 | 0.310 |
Why?
| | Orbital Myositis | 1 | 2007 | 2 | 0.290 |
Why?
| | Oculomotor Muscles | 1 | 2007 | 40 | 0.280 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2007 | 58 | 0.280 |
Why?
| | Albinism, Ocular | 1 | 2005 | 1 | 0.260 |
Why?
| | Nystagmus, Pathologic | 1 | 2005 | 7 | 0.260 |
Why?
| | Albinism, Oculocutaneous | 1 | 2005 | 6 | 0.260 |
Why?
| | Apolipoprotein E4 | 2 | 2016 | 33 | 0.220 |
Why?
| | Gyrus Cinguli | 2 | 2016 | 69 | 0.220 |
Why?
| | Feedback | 1 | 2022 | 149 | 0.200 |
Why?
| | Neuromyelitis Optica | 1 | 2023 | 114 | 0.190 |
Why?
| | Brain | 1 | 2012 | 2372 | 0.190 |
Why?
| | Recurrence | 1 | 2024 | 950 | 0.190 |
Why?
| | Humans | 17 | 2024 | 115879 | 0.180 |
Why?
| | Visual Acuity | 2 | 2016 | 273 | 0.180 |
Why?
| | Immunosuppressive Agents | 1 | 2024 | 666 | 0.170 |
Why?
| | Stem Cells | 1 | 2023 | 546 | 0.160 |
Why?
| | Faculty, Nursing | 1 | 2018 | 22 | 0.160 |
Why?
| | Education, Distance | 1 | 2018 | 36 | 0.160 |
Why?
| | Visual Cortex | 1 | 2016 | 41 | 0.140 |
Why?
| | Personal Satisfaction | 1 | 2018 | 185 | 0.140 |
Why?
| | Postoperative Complications | 1 | 2007 | 2164 | 0.140 |
Why?
| | Eye | 1 | 2016 | 101 | 0.130 |
Why?
| | Neurosurgical Procedures | 2 | 2014 | 157 | 0.130 |
Why?
| | Spatial Behavior | 1 | 2015 | 21 | 0.130 |
Why?
| | Vision Disorders | 1 | 2016 | 130 | 0.130 |
Why?
| | Learning | 1 | 2018 | 358 | 0.120 |
Why?
| | Electron Transport Complex IV | 2 | 2012 | 53 | 0.120 |
Why?
| | Neuroimaging | 1 | 2016 | 248 | 0.120 |
Why?
| | Oligodendroglioma | 1 | 2013 | 15 | 0.120 |
Why?
| | Neural Pathways | 1 | 2015 | 260 | 0.110 |
Why?
| | Vision Screening | 1 | 2013 | 9 | 0.110 |
Why?
| | Pilot Projects | 1 | 2018 | 1379 | 0.110 |
Why?
| | Evoked Potentials, Visual | 1 | 2013 | 31 | 0.110 |
Why?
| | Retinal Neoplasms | 1 | 2013 | 21 | 0.110 |
Why?
| | Retinoblastoma | 1 | 2013 | 26 | 0.110 |
Why?
| | Synaptophysin | 1 | 2012 | 11 | 0.100 |
Why?
| | Radionuclide Imaging | 1 | 2012 | 121 | 0.100 |
Why?
| | Maze Learning | 1 | 2012 | 87 | 0.100 |
Why?
| | Amyloidosis | 1 | 2012 | 36 | 0.100 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2012 | 82 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2013 | 312 | 0.100 |
Why?
| | tau Proteins | 1 | 2012 | 67 | 0.100 |
Why?
| | Glioblastoma | 1 | 2014 | 251 | 0.100 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2013 | 690 | 0.090 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2012 | 125 | 0.090 |
Why?
| | Radiopharmaceuticals | 1 | 2012 | 188 | 0.090 |
Why?
| | Genetic Carrier Screening | 1 | 2010 | 24 | 0.090 |
Why?
| | Plant Extracts | 1 | 2012 | 153 | 0.090 |
Why?
| | Female | 9 | 2019 | 60082 | 0.090 |
Why?
| | Radiosurgery | 1 | 2013 | 298 | 0.090 |
Why?
| | Reoperation | 2 | 2014 | 525 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 796 | 0.080 |
Why?
| | Psychomotor Performance | 1 | 2012 | 278 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2014 | 863 | 0.080 |
Why?
| | Aged | 3 | 2019 | 19296 | 0.080 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1644 | 0.070 |
Why?
| | Sex Characteristics | 1 | 2012 | 643 | 0.070 |
Why?
| | Prednisolone | 1 | 2007 | 77 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2365 | 0.070 |
Why?
| | Postoperative Period | 1 | 2007 | 292 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2014 | 979 | 0.070 |
Why?
| | Vision, Binocular | 1 | 2005 | 15 | 0.060 |
Why?
| | Cognition | 1 | 2012 | 980 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2013 | 12616 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2014 | 9164 | 0.060 |
Why?
| | Mitochondria | 1 | 2010 | 750 | 0.060 |
Why?
| | Male | 7 | 2016 | 56117 | 0.060 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 43 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2007 | 552 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 4780 | 0.050 |
Why?
| | Animals | 2 | 2015 | 32162 | 0.050 |
Why?
| | Inflammation | 1 | 2012 | 2502 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2201 | 0.050 |
Why?
| | Adolescent | 3 | 2010 | 17940 | 0.040 |
Why?
| | Adult | 5 | 2016 | 30822 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2023 | 782 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2007 | 2404 | 0.040 |
Why?
| | Disease Progression | 2 | 2014 | 2423 | 0.040 |
Why?
| | Amino Acid Transport System X-AG | 1 | 2016 | 4 | 0.030 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2016 | 21 | 0.030 |
Why?
| | Hexokinase | 1 | 2016 | 10 | 0.030 |
Why?
| | Mice | 1 | 2012 | 15087 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1362 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 219 | 0.030 |
Why?
| | Tissue Fixation | 1 | 2013 | 28 | 0.030 |
Why?
| | Risk Factors | 1 | 2007 | 8715 | 0.030 |
Why?
| | Infusions, Intra-Arterial | 1 | 2013 | 45 | 0.030 |
Why?
| | Cryotherapy | 1 | 2013 | 16 | 0.030 |
Why?
| | Microsurgery | 1 | 2013 | 61 | 0.030 |
Why?
| | Hyperthermia, Induced | 1 | 2013 | 65 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2013 | 182 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2013 | 621 | 0.030 |
Why?
| | Meningioma | 1 | 2013 | 78 | 0.030 |
Why?
| | Middle Aged | 2 | 2014 | 27085 | 0.020 |
Why?
| | Child, Preschool | 1 | 2005 | 9165 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 816 | 0.020 |
Why?
| | Nervous System Diseases | 1 | 2013 | 253 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1218 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1127 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 2581 | 0.020 |
Why?
| | Young Adult | 2 | 2016 | 10510 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 818 | 0.020 |
Why?
| | Child | 1 | 2005 | 18539 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 3344 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2013 | 4444 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2014 | 6434 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 1891 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2013 | 3072 | 0.010 |
Why?
| | Infant | 1 | 2013 | 7992 | 0.010 |
Why?
| | United States | 1 | 2014 | 12322 | 0.010 |
Why?
|
|
Wolf's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|